Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan Ashley

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2005
Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survivalMitch Dowsett, Ian E Smith, Steve R Ebbs, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2005
Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialistsMitch Dowsett, Steve R Ebbs, J Michael Dixon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2006
Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancerMitch Dowsett, Ian E Smith, Steve R Ebbs, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2005
Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survivalMitch Dowsett, Ian E Smith, Steve R Ebbs, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2005
Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialistsMitch Dowsett, Steve R Ebbs, J Michael Dixon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2006
Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancerMitch Dowsett, Ian E Smith, Steve R Ebbs, et al.
Pageof 2